

Shareholder Primacy
Free Float Media Inc.
From activist investor and advisor Mike Levin and Colorado Law professor Ann Lipton, Shareholder Primacy is a podcast about activist investing, securities law, and all the ways the financial and legal worlds intersect and collide in real life.
Episodes
Mentioned books

Dec 17, 2025 • 1h 3min
2026 Predictions with Matt Moscardi + Damion Rallis of the Proxy Countdown podcast
2026 Predictions with Matt Moscardi + Damion Rallis of the Proxy Countdown podcast

Dec 10, 2025 • 44min
What Activists Are Doing Right Now
Mike and Ann dive into the hustle and bustle of activist work, especially during the year-end rush. They explore the three-year timeline of activism, detailing everything from analysis to results. December's significant role is highlighted, tied to fiscal year ends and proxy planning. Ann discusses strategies like targeting directors and using bylaw amendments as pressure tactics. They also touch on how boards detect activist presence and the implications of recent SEC policy changes. ESG activism concerns and its unique calendar are also examined.

14 snips
Dec 3, 2025 • 41min
Proxy Advisors and Activism
Ann and Mike delve into the evolving landscape of proxy advisors amidst legal pressures. They discuss how ISS and Glass Lewis are adapting their business models and the implications for shareholder activism. Insights include the shift from blanket recommendations to customized policies and the growing importance of analytics. The conflict between companies and proxy advisors over executive compensation comes to light, alongside the anticipated resilience of these firms in catering to loyal clients. Other topics encompass regulatory scrutiny and the impact on activism in corporate governance.

Nov 19, 2025 • 46min
Kyle Pinder on shareholder proposals under Delaware law
Mike talks with attorney Kyle Pinder about his research about shareholder proposals under Delaware law.

15 snips
Nov 12, 2025 • 36min
Legal and financial questions of Pfizer-Novo-Metsera
In a thrilling battle for MetSera, Pfizer and Novo Nordisk engage in a fierce competition driven by the value of GLP-1 drugs. The discussion delves into intricate deal structures, including cash-plus-contingent-value-right offers typical in pharma M&A. Antitrust risks loom large, with regulatory implications complicating Novo's bid strategy. The hosts dissect the legal maneuvers, and lawsuits, and unravel how litigation pressure forced Pfizer to elevate its offers. Ultimately, they ponder who emerged victorious and what lies ahead for MetSera and its shareholders.

Nov 5, 2025 • 42min
Relationship of federal and state corporation law
Ann and Mike talk about the relationship of federal and state corporate law.

Oct 29, 2025 • 36min
Universal proxy after three years
Ann and Mike talk about universal proxy after three years

Oct 22, 2025 • 45min
Shareholder proposals and Delaware law
Ann and Mike talk about SEC Chair Atkins’ speech before the Weinberg Center about shareholder proposals and their relation to Delaware law

9 snips
Oct 15, 2025 • 33min
Majority vote standards, bylaw amendments
In this discussion, hosts delve into the complexities of majority vote standard proposals and bylaw amendments. They explore Duke Energy's struggle with high charter amendment thresholds, highlighting the history of repeated shareholder initiatives. The hosts clarify the difference between precatory and binding proposals and analyze the motivations behind boards stalling shareholder-driven changes. They offer insights into the legal landscape surrounding bylaw amendments and suggest strategies for strengthening shareholder influence. A captivating exploration of corporate governance dynamics!

Oct 8, 2025 • 32min
M&A litigation, corporate personhood
Ann and Mike talk about M&A litigation in a recent important case and whether corporations are people


